Exelixis, Inc. Share Price Today: Live Updates & Key Insights
Exelixis, Inc. share price today is $55.37, up -0.5%. The stock opened at $55.77 against the previous close of $55.65, with an intraday high of $56.015 and low of $55.11.
Exelixis, Inc. Share Price Chart
Exelixis, Inc.
Exelixis, Inc. Share Price Performance
Exelixis, Inc. Institutional Holdings
Exelixis, Inc. Market Status
Exelixis, Inc. Fundamentals
Market Cap 13987.91 M
PB Ratio 7.1423
PE Ratio 18.4272
Enterprise Value 13218.12 M
Total Assets 2844.42 M
Volume 1838009
Exelixis, Inc. Company Financials
About Exelixis, Inc. & investment objective
Company Information Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Organisation Biotechnology
Employees 1077
Industry Biotechnology
CEO Dr. Michael M. Morrissey Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:
Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*
Take your next step
Exelixis, Inc. FAQs
What is the share price of Exelixis, Inc. today?
The current share price of Exelixis, Inc. is $55.37.
Can I buy Exelixis, Inc. shares in India?
Yes, Indian investors can buy Exelixis, Inc. shares by opening an international trading and demat account with Motilal Oswal.
How to buy Exelixis, Inc. shares in India?
You can easily invest in Exelixis, Inc. shares from India by:
- Direct Investment:
Opening an international trading account with Motilal Oswal which includes KYC verification in the US. Your account gets activated in a few minutes to a few hours, after which you can start adding funds in USD balance to buy Exelixis, Inc. shares. - Indirect Investment:
Under this form of investment, you can choose either a Mutual Fund (MF) or an Exchange-Traded Fund (ETF) that invests in global shares and start investing in shares of Exelixis, Inc..
Can I buy fractional shares of Exelixis, Inc.?
Yes, many platforms allow you to buy fractional shares starting from as low as $1.
What is the market capitalization value of Exelixis, Inc.?
Exelixis, Inc. has a market cap of $13987.91 M.
In which sector does Exelixis, Inc. belong?
Exelixis, Inc. operates in the Biotechnology sector.
What documents are required to invest in Exelixis, Inc. stocks?
To invest, you typically need:
What is the PE and PB ratio of Exelixis, Inc.?
The PE ratio of Exelixis, Inc. is 18.43 and the PB ratio is 7.14.